Chapter 2 Natural Killer Cell Tolerance. Licensing and Other Mechanisms

Advances in Immunology

Volumn 101, Issue C, 2009, Pages 27-79

  Jonsson, A Helena ^a   Yokoyama, Wayne M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; CYTOKINE; NATURAL KILLER CELL LECTIN LIKE RECEPTOR; NATURAL KILLER CELL RECEPTOR;

AUTOIMMUNE DISEASE; CANCER IMMUNOTHERAPY; CELL ACTIVATION; CELL FUNCTION; CELL MEMBRANE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; NATURAL KILLER T CELL; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; ANIMAL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; NATURAL KILLER CELL;

ANIMALS; AUTOIMMUNE DISEASES; CYTOKINES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; MAJOR HISTOCOMPATIBILITY COMPLEX; RECEPTORS, NATURAL KILLER CELL; RECEPTORS, NK CELL LECTIN-LIKE;

EID: 60449110935     PISSN: 00652776     EISSN: 15578445     Source Type: Book Series    
DOI: 10.1016/S0065-2776(08)01002-X     Document Type: Review

References (214)

1. Adams E.J., Juo Z.S., Venook R.T., Boulanger M.J., Arase H., Lanier L.L., and Garcia K.C. Structural elucidation of the m157 mouse cytomegalovirus ligand for Ly49 natural killer cell receptors. Proc. Natl. Acad. Sci. USA 104 (2007) 10128-10133
2. Agazie Y.M., and Hayman M.J. Molecular mechanism for a role of SHP2 in epidermal growth factor receptor signaling. Mol. Cell Biol. 23 (2003) 7875-7886
3. Alcami A., and Koszinowski U.H. Viral mechanisms of immune evasion. Immunol. Today 21 (2000) 447-455
4. Algarra I., Garcia-Lora A., Cabrera T., Ruiz-Cabello F., and Garrido F. The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: Implications for tumor immune escape. Cancer Immunol. Immunother. 53 (2004) 904-910
5. An H., Hou J., Zhou J., Zhao W., Xu H., Zheng Y., Yu Y., Liu S., and Cao X. Phosphatase SHP-1 promotes TLR- and RIG-I-activated production of type I interferon by inhibiting the kinase IRAK1. Nat. Immunol. 9 (2008) 542-550
6. Andersson K.E., Williams G.S., Davis D.M., and Hoglund P. Quantifying the reduction in accessibility of the inhibitory NK cell receptor Ly49A caused by binding MHC class I proteins in cis. Eur. J. Immunol. 37 (2007) 516-527
7. Andersson M., Freland S., Johansson M.H., Wallin R., Sandberg J.K., Chambers B.J., Christensson B., Lendahl U., Lemieux S., Salcedo M., and Ljunggren H.G. MHC class I mosaic mice reveal insights into control of Ly49C inhibitory receptor expression in NK cells. J. Immunol. 161 (1998) 6475-6479
8. Andoniou C.E., van Dommelen S.L., Voigt V., Andrews D.M., Brizard G., Asselin-Paturel C., Delale T., Stacey K.J., Trinchieri G., and Degli-Esposti M.A. Interaction between conventional dendritic cells and natural killer cells is integral to the activation of effective antiviral immunity. Nat. Immunol. 6 (2005) 1011-1019
9. Anfossi N., Andre P., Guia S., Falk C.S., Roetynck S., Stewart C.A., Breso V., Frassati C., Reviron D., Middleton D., Romagne F., Ugolini S., and Vivier E. Human NK cell education by inhibitory receptors for MHC class I. Immunity 25 (2006) 331-342
10. Arase H., Mocarski E.S., Campbell A.E., Hill A.B., and Lanier L.L. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296 (2002) 1323-1326
11. Ashkar A.A., Di Santo J.P., and Croy B.A. Interferon gamma contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy. J. Exp. Med. 192 (2000) 259-270
12. Avril T., North S.J., Haslam S.M., Willison H.J., and Crocker P.R. Probing the cis interactions of the inhibitory receptor Siglec-7 with {alpha}2,8-disialylated ligands on natural killer cells and other leukocytes using glycan-specific antibodies and by analysis of {alpha}2,8-sialyltransferase gene expression. J. Leukoc. Biol. 80 (2006) 787-796
13. Back J., Chalifour A., Scarpellino L., and Held W. Stable masking by H-2Dd cis ligand limits Ly49A relocalization to the site of NK cell/target cell contact. Proc. Natl. Acad. Sci. USA 104 (2007) 3978-3983
14. Barao I., Hanash A.M., Hallett W., Welniak L.A., Sun K., Redelman D., Blazar B.R., Levy R.B., and Murphy W.J. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc. Natl. Acad. Sci. USA 103 (2006) 5460-5465
15. Barber M.A., Zhang T., Gagne B.A., Van Ginderachter J.A., De Baetselier P., and Sentman C.L. Ly49G2 receptor blockade reduces tumor burden in a leukemia model but not in a solid tumor model. Cancer Immunol. Immunother 57 (2008) 655-662
16. Barten R., Torkar M., Haude A., Trowsdale J., and Wilson M.J. Divergent and convergent evolution of NK-cell receptors. Trends Immunol. 22 (2001) 52-57
17. Bashirova A.A., Martin M.P., McVicar D.W., and Carrington M. The killer immunoglobulin-like receptor gene cluster: Tuning the genome for defense. Annu. Rev. Genomics Hum. Genet. 7 (2006) 277-300
18. Biron C.A., Nguyen K.B., Pien G.C., Cousens L.P., and Salazar-Mather T.P. Natural killer cells in antiviral defense: Function and regulation by innate cytokines. Annu. Rev. Immunol. 17 (1999) 189-220
19. Bryceson Y.T., March M.E., Ljunggren H.G., and Long E.O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214 (2006) 73-91
20. Bryceson Y.T., March M.E., Ljunggren H.G., and Long E.O. Synergy among receptors on resting NK cells for the activation of natural cytotoxicity and cytokine secretion. Blood 107 (2006) 159-166
21. Bulmer J.N., Morrison L., Longfellow M., Ritson A., and Pace D. Granulated lymphocytes in human endometrium: Histochemical and immunohistochemical studies. Hum. Reprod. 6 (1991) 791-798
22. Burshtyn D.N., Shin J., Stebbins C., and Long E.O. Adhesion to target cells is disrupted by the killer cell inhibitory receptor. Curr. Biol. 10 (2000) 777-780
23. Caraux A., Lu Q., Fernandez N., Riou S., Di Santo J.P., Raulet D.H., Lemke G., and Roth C. Natural killer cell differentiation driven by Tyro3 receptor tyrosine kinases. Nat. Immunol. 7 (2006) 747-754
24. Carayannopoulos L.N., Naidenko O.V., Kinder J., Ho E.L., Fremont D.H., and Yokoyama W.M. Ligands for murine NKG2D display heterogeneous binding behavior. Eur. J. Immunol. 32 (2002) 597-605
25. Carlyle J.R., Jamieson A.M., Gasser S., Clingan C.S., Arase H., and Raulet D.H. Missing self-recognition of Ocil/Clr-b by inhibitory NKR-P1 natural killer cell receptors. Proc. Natl. Acad. Sci. USA 101 (2004) 3527-3532
26. Carnaud C., Lee D., Donnars O., Park S.H., Beavis A., Koezuka Y., and Bendelac A. Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J. Immunol. 163 (1999) 4647-4650
27. Carrington M., Wang S., Martin M.P., Gao X., Schiffman M., Cheng J., Herrero R., Rodriguez A.C., Kurman R., Mortel R., Schwartz P., Glass A., and Hildesheim A. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J. Exp. Med. 201 (2005) 1069-1075
28. Caumartin J., Favier B., Daouya M., Guillard C., Moreau P., Carosella E.D., and LeMaoult J. Trogocytosis-based generation of suppressive NK cells. EMBO J. 26 (2007) 1423-1433
29. Cella M., Longo A., Ferrara G.B., Strominger J.L., and Colonna M. NK3-specific natural killer cells are selectively inhibited by Bw4-positive HLA alleles with isoleucine 80. J. Exp. Med. 180 (1994) 1235-1242
30. Cerwenka A., Bakker A.B.H., McClanahan T., Wagner J., Wu J., Phillips J.H., and Lanier L.L. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity 12 (2000) 721-727
31. Chan A., Hong D.L., Atzberger A., Kollnberger S., Filer A.D., Buckley C.D., McMichael A., Enver T., and Bowness P. CD56bright human NK cells differentiate into CD56dim cells: Role of contact with peripheral fibroblasts. J. Immunol. 179 (2007) 89-94
32. Chang C.C., Campoli M., and Ferrone S. Classical and nonclassical HLA class I antigen and NK Cell-activating ligand changes in malignant cells: Current challenges and future directions. Adv. Cancer Res. 93 (2005) 189-234
33. Chung D.H., Natarajan K., Boyd L.F., Tormo J., Mariuzza R.A., Yokoyama W.M., and Margulies D.H. Mapping the ligand of the NK inhibitory receptor Ly49A on living cells. J. Immunol. 165 (2000) 6922-6932
34. Colonna M., and Samaridis J. Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells. Science 268 (1995) 405-408
35. Cooley S., Xiao F., Pitt M., Gleason M., McCullar V., Bergemann T.L., McQueen K.L., Guethlein L.A., Parham P., and Miller J.S. A subpopulation of human peripheral blood NK cells that lacks inhibitory receptors for self-MHC is developmentally immature. Blood 110 (2007) 578-586
36. Cooper M.A., Fehniger T.A., Turner S.C., Chen K.S., Ghaheri B.A., Ghayur T., Carson W.E., and Caligiuri M.A. Human natural killer cells: A unique innate immunoregulatory role for the CD56(bright) subset. Blood 97 (2001) 3146-3151
37. Coudert J.D., Scarpellino L., Gros F., Vivier E., and Held W. Sustained NKG2D engagement induces cross-tolerance of multiple distinct NK cell activation pathways. Blood 111 (2008) 3571-3578
38. Cudkowicz G., and Stimpfling J.H. Hybrid resistance to parental marrow grafts: Association with the K region of H-2. Science 144 (1964) 1339-1340
39. Dam J., Baber J., Grishaev A., Malchiodi E.L., Schuck P., Bax A., and Mariuzza R.A. Variable dimerization of the Ly49A natural killer cell receptor results in differential engagement of its MHC class I ligand. J. Mol. Biol. 362 (2006) 102-113
40. Dam J., Guan R., Natarajan K., Dimasi N., Chlewicki L.K., Kranz D.M., Schuck P., Margulies D.H., and Mariuzza R.A. Variable MHC class I engagement by Ly49 natural killer cell receptors demonstrated by the crystal structure of Ly49C bound to H-2K(b). Nat. Immunol. 4 (2003) 1213-1222
41. Dann S.M., Wang H.C., Gambarin K.J., Actor J.K., Robinson P., Lewis D.E., Caillat-Zucman S., and White Jr. A.C. Interleukin-15 activates human natural killer cells to clear the intestinal protozoan cryptosporidium. J. Infect. Dis. 192 (2005) 1294-1302
42. Davis D.M. Intercellular transfer of cell-surface proteins is common and can affect many stages of an immune response. Nat. Rev. Immunol. 7 (2007) 238-243
43. Deng L., and Mariuzza R.A. Structural basis for recognition of MHC and MHC-like ligands by natural killer cell receptors. Semin. Immunol. 18 (2006) 159-166
44. Deniz G., Erten G., Kucuksezer U.C., Kocacik D., Karagiannidis C., Aktas E., Akdis C.A., and Akdis M. Regulatory NK cells suppress antigen-specific T cell responses. J. Immunol. 180 (2008) 850-857
45. Diefenbach A., Jamieson A.M., Liu S.D., Shastri N., and Raulet D.H. Ligands for the murine NKG2D receptor: Expression by tumor cells and activation of NK cells and macrophages. Nat. Immunol. 1 (2000) 119-126
46. Diefenbach A., Tomasello E., Lucas M., Jamieson A.M., Hsia J.K., Vivier E., and Raulet D.H. Selective associations with signaling molecules determine stimulatory versus costimulatory activity of NKG2D. Nat. Immunol. 3 (2002) 1142-1149
47. Dokun A.O., Kim S., Smith H.R., Kang H.S., Chu D.T., and Yokoyama W.M. Specific and nonspecific NK cell activation during virus infection. Nat. Immunol. 2 (2001) 951-956
48. Dorfman J.R., and Raulet D.H. Acquisition of Ly49 receptor expression by developing natural killer cells. J. Exp. Med. 187 (1998) 609-618
49. Doucey M.A., Scarpellino L., Zimmer J., Guillaume P., Luescher I.F., Bron C., and Held W. Cis association of Ly49A with MHC class I restricts natural killer cell inhibition. Nat. Immunol. 5 (2004) 328-336
50. Farag S.S., and Caligiuri M.A. Human natural killer cell development and biology. Blood Rev. 20 (2006) 123-137
51. Faure M., Barber D.F., Takahashi S.M., Jin T., and Long E.O. Spontaneous clustering and tyrosine phosphorylation of NK cell inhibitory receptor induced by ligand binding. J. Immunol. 170 (2003) 6107-6114
52. Fehniger T.A., Cai S.F., Cao X., Bredemeyer A.J., Presti R.M., French A.R., and Ley T.J. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity 26 (2007) 798-811
53. Ferlazzo G., Tsang M.L., Moretta L., Melioli G., Steinman R.M., and Munz C. Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells. J. Exp. Med. 195 (2002) 343-351
54. Fernandez N.C., Lozier A., Flament C., Ricciardi-Castagnoli P., Bellet D., Suter M., Perricaudet M., Tursz T., Maraskovsky E., and Zitvogel L. Dendritic cells directly trigger NK cell functions: Cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5 (1999) 405-411
55. Fernandez N.C., Treiner E., Vance R.E., Jamieson A.M., Lemieux S., and Raulet D.H. A subset of natural killer cells achieves self-tolerance without expressing inhibitory receptors specific for self-MHC molecules. Blood 105 (2005) 4416-4423
56. Fourmentraux-Neves E., Jalil A., Da Rocha S., Pichon C., Chouaib S., Bismuth G., and Caignard A. Two opposite signaling outputs are driven by the KIR2DL1 receptor in human CD4+ T cells. Blood 112 (2008) 2381-2389
57. French A.R., Sjolin H., Kim S., Koka R., Yang L., Young D.A., Cerboni C., Tomasello E., Ma A., Vivier E., Karre K., and Yokoyama W.M. DAP12 signaling directly augments proproliferative cytokine stimulation of NK Cells during viral infections. J. Immunol. 177 (2006) 4981-4990
58. French A.R., and Yokoyama W.M. Natural killer cells and autoimmunity. Arthritis Res. Ther. 6 (2004) 8-14
59. Gardiner C.M. Killer cell immunoglobulin-like receptors on NK cells: The how, where and why. Int. J. Immunogenet 35 (2008) 1-8
60. Gasser S., Orsulic S., Brown E.J., and Raulet D.H. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 436 (2005) 1186-1190
61. Gasser S., and Raulet D.H. Activation and self-tolerance of natural killer cells. Immunol. Rev. 214 (2006) 130-142
62. George T.C., Mason L.H., Ortaldo J.R., Kumar V., and Bennett M. Positive recognition of MHC class I molecules by the Ly49D receptor of murine NK cells. J. Immunol. 162 (1999) 2035-2043
63. George T.C., Ortaldo J.R., Lemieux S., Kumar V., and Bennett M. Tolerance and alloreactivity of the Ly49D subset of murine NK cells. J. Immunol. 163 (1999) 1859-1867
64. Gerosa F., Baldani-Guerra B., Nisii C., Marchesini V., Carra G., and Trinchieri G. Reciprocal activating interaction between natural killer cells and dendritic cells. J. Exp. Med. 195 (2002) 327-333
65. Ghiringhelli F., Menard C., Martin F., and Zitvogel L. The role of regulatory T cells in the control of natural killer cells: Relevance during tumor progression. Immunol. Rev. 214 (2006) 229-238
66. Ghiringhelli F., Menard C., Terme M., Flament C., Taieb J., Chaput N., Puig P.E., Novault S., Escudier B., Vivier E., Lecesne A., Robert C., et al. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J. Exp. Med. 202 (2005) 1075-1085
67. Gilfillan S., Ho E.L., Cella M., Yokoyama W.M., and Colonna M. NKG2D recruits two distinct adapters to trigger natural killer cell activation and costimulation. Nature Immunol. 3 (2002) 1150-1155
68. Giuliani M., Giron-Michel J., Negrini S., Vacca P., Durali D., Caignard A., Le Bousse-Kerdiles C., Chouaib S., Devocelle A., Bahri R., Durrbach A., Taoufik Y., et al. Generation of a novel regulatory NK cell subset from peripheral blood CD34+ progenitors promoted by membrane-bound IL-15. PLoS ONE 3 (2008) e2241
69. Grimm E.A., Mazumder A., Zhang H.Z., and Rosenberg S.A. Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J. Exp. Med. 155 (1982) 1823-1841
70. Groh V., Bahram S., Bauer S., Herman A., Beauchamp M., and Spies T. Cell stress-regulated human major histocompatibility complex class I gene expressed in gastrointestinal epithelium. Proc. Natl. Acad. Sci. USA 93 (1996) 12445-12450
71. Groh V., Wu J., Yee C., and Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 419 (2002) 734-738
72. Grzywacz B., Kataria N., Sikora M., Oostendorp R.A., Dzierzak E.A., Blazar B.R., Miller J.S., and Verneris M.R. Coordinated acquisition of inhibitory and activating receptors and functional properties by developing human natural killer cells. Blood 108 (2006) 3824-3833
73. Guerra N., Tan Y.X., Joncker N.T., Choy A., Gallardo F., Xiong N., Knoblaugh S., Cado D., Greenberg N.M., and Raulet D.H. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28 (2008) 571-580
74. Gumperz J.E., Litwin V., Phillips J.H., Lanier L.L., and Parham P. The Bw4 public epitope of HLA-B molecules confers reactivity with natural killer cell clones that express NKB1, a putative HLA receptor. J. Exp. Med. 181 (1995) 1133-1144
75. Gumperz J.E., and Parham P. The enigma of the natural killer cell. Nature 378 (1995) 245-248
76. Hanke T., Takizawa H., McMahon C.W., Busch D.H., Pamer E.G., Miller J.D., Altman J.D., Liu Y., Cado D., Lemonnier F.A., Bjorkman P.J., and Raulet D.H. Direct assessment of MHC class I binding by seven Ly49 inhibitory NK cell receptors. Immunity 11 (1999) 67-77
77. Hanna J., Goldman-Wohl D., Hamani Y., Avraham I., Greenfield C., Natanson-Yaron S., Prus D., Cohen-Daniel L., Arnon T.I., Manaster I., Gazit R., Yutkin V., et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12 (2006) 1065-1074
78. Held W., Dorfman J.R., Wu M.F., and Raulet D.H. Major histocompatibility complex class I dependent skewing of the natural killer cell LY49 receptor repertoire. Eur. J. Immunol. 26 (1996) 2286-2292
79. Held W., and Mariuzza R.A. Cis interactions of immunoreceptors with MHC and non-MHC ligands. Nat. Rev. Immunol. 8 (2008) 269-278
80. Hiby S.E., Walker J.J., O'Shaughnessy K.M., Redman C.W., Carrington M., Trowsdale J., and Moffett A. Combinations of maternal KIR and fetal HLA-C genes influence the risk of preeclampsia and reproductive success. J. Exp. Med. 200 (2004) 957-965
81. Ho E.L., Carayannopoulos L.N., Poursine-Laurent J., Kinder J., Plougastel B., Smith H.R.C., and Yokoyama W.M. Co-stimulation of multiple NK cell activation receptors by NKG2D. J. Immunol. 169 (2002) 3667-3675
82. Hoglund P., Ohlen C., Carbone E., Franksson L., Ljunggren H.G., Latour A., Koller B., and Kärre K. Recognition of beta 2-microglobulin- negative (beta 2m-) T-cell blasts by natural killer cells from normal but not from beta 2m- mice: Nonresponsiveness controlled by beta 2m- bone marrow in chimeric mice. Proc. Natl. Acad. Sci. USA 88 (1991) 10332-10336
83. Hoglund P., Sundback J., Olssonalheim M.Y., Johansson M., Salcedo M., Ohlen C., Ljunggren H.G., Sentman C.L., and Karre K. Host MHC class I gene control of NK-cell specificity in the mouse. Immunol. Rev. 155 (1997) 11-28
84. Igarashi T., Wynberg J., Srinivasan R., Becknell B., McCoy Jr. J.P., Takahashi Y., Suffredini D.A., Linehan W.M., Caligiuri M.A., and Childs R.W. Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood 104 (2004) 170-177
85. Iizuka K., Naidenko O.V., Plougastel B.F., Fremont D.H., and Yokoyama W.M. Genetically linked C-type lectin-related ligands for the NKRP1 family of natural killer cell receptors. Nat. Immunol. 4 (2003) 801-807
86. Ioannidis V., Zimmer J., Beermann F., and Held W. Cre Recombinase-Mediated Inactivation of H-2D(d) Transgene expression: Evidence for partial missing self-recognition by Ly49A NK cells. J. Immunol. 167 (2001) 6256-6262
87. Jacobs R., Hintzen G., Kemper A., Beul K., Kempf S., Behrens G., Sykora K.W., and Schmidt R.E. CD56bright cells differ in their KIR repertoire and cytotoxic features from CD56dim NK cells. Eur. J. Immunol. 31 (2001) 3121-3127
88. Johansson M.H., Bieberich C., Jay G., Karre K., and Hoglund P. Natural killer cell tolerance in mice with mosaic expression of major histocompatibility complex class I transgene. J. Exp. Med. 186 (1997) 353-364
89. Johansson M.H., Bieberich C., Kase-Sjostrom A., Yoshioka T., Hoglund E., Christy B.A., Scangos G., Karre K., Jay G., and Hoglund P. Differential effects on T cell and NK cell development by tissue-specific expression of H-2D(d) transgene. Eur. J. Immunol. 30 (2000) 525-533
90. Johansson M.H., and Hoglund P. Low number of H-2Dd-negative haematopoietic cells in mixed bone marrow chimeras convey in vivo tolerance to H-2Dd-negative cells but fail to prevent resistance to H-2Dd-negative leukaemia. Scand J. Immunol. 59 (2004) 71-78
91. Johansson S., Johansson M., Rosmaraki E., Vahlne G., Mehr R., Salmon-Divon M., Lemonnier F., Karre K., and Hoglund P. Natural killer cell education in mice with single or multiple major histocompatibility complex class I molecules. J. Exp. Med. 201 (2005) 1145-1155
92. Jones D.C., Edgar R.S., Ahmad T., Cummings J.R., Jewell D.P., Trowsdale J., and Young N.T. Killer Ig-like receptor (KIR) genotype and HLA ligand combinations in ulcerative colitis susceptibility. Genes. Immun. 7 (2006) 576-582
93. Karlhofer F.M., Hunziker R., Reichlin A., Margulies D.H., and Yokoyama W.M. Host MHC class I molecules modulate in vivo expression of a NK cell receptor. J. Immunol. 153 (1994) 2407-2416
94. Karlhofer F.M., Ribaudo R.K., and Yokoyama W.M. MHC class I alloantigen specificity of Ly-49+ IL-2-activated natural killer cells. Nature 358 (1992) 66-70
95. Karlhofer F.M., and Yokoyama W.M. Stimulation of murine natural killer (NK) cells by a monoclonal antibody specific for the NK1.1 antigen. IL-2-activated NK cells possess additional specific stimulation pathways. J. Immunol. 146 (1991) 3662-3673
96. Karre K., Ljunggren H.-G., Piontek G., and Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 (1986) 675-678
97. Kärre K., Ljunggren H.G., Piontek G., and Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319 (1986) 675-678
98. Kase A., Johansson M.H., Olsson-Alheim M.Y., Karre K., and Hoglund P. External and internal calibration of the MHC class I-specific receptor Ly49A on murine natural killer cells. J. Immunol. 161 (1998) 6133-6138
99. Kaufman D.S., Schoon R.A., Robertson M.J., and Leibson P.J. Inhibition of selective signaling events in natural killer cells recognizing major histocompatibility complex class I. Proc. Nat. Acad. Sci. USA 92 (1995) 6484-6488
100. Kelley J., Walter L., and Trowsdale J. Comparative genomics of natural killer cell receptor gene clusters. PLoS Genet. 1 (2005) 129-139
101. Khakoo S.I., Thio C.L., Martin M.P., Brooks C.R., Gao X., Astemborski J., Cheng J., Goedert J.J., Vlahov D., Hilgartner M., Cox S., Little A.M., et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science 305 (2004) 872-874
102. Kim K.D., Zhao J., Auh S., Yang X., Du P., Tang H., and Fu Y.X. Adaptive immune cells temper initial innate responses. Nat. Med. 13 (2007) 1248-1252
103. Kim S., Iizuka K., Kang H.S., Dokun A., French A.R., Greco S., and Yokoyama W.M. In vivo developmental stages in murine natural killer cell maturation. Nature Immunol. 3 (2002) 523-528
104. Kim S., Poursine-Laurent J., Truscott S.M., Lybarger L., Song Y.J., Yang L., French A.R., Sunwoo J.B., Lemieux S., Hansen T.H., and Yokoyama W.M. Licensing of natural killer cells by host major histocompatibility complex class I molecules. Nature 436 (2005) 709-713
105. Kim S., Sunwoo J.B., Yang L., Choi T., Song Y.J., French A.R., Vlahiotis A., Piccirillo J.F., Cella M., Colonna M., Mohanakumar T., Hsu K.C., et al. HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl. Acad. Sci. USA 105 (2008) 3053-3058
106. Koh C.Y., Blazar B.R., George T., Welniak L.A., Capitini C.M., Raziuddin A., Murphy W.J., and Bennett M. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 97 (2001) 3132-3137
107. Krug A., French A.R., Barchet W., Fischer J.A.A., Dzionek A., Pingel J.T., Orihuela M.M., Akira S., Yokoyama W.M., and Colonna M. TLR9-dependent recognition of MCMV by IPC and DC generates coordinated cytokine responses that activate antiviral NK cell function. Immunity 21 (2004) 107-119
108. Kulkarni S., Martin M.P., and Carrington M. The Yin and Yang of HLA and KIR in human disease. Semin. Immunol. (2008) Prepublished online July 15, 2008; DOI 10.1016/j.smim.2008.06.003
109. Kumar V., and McNerney M.E. A new self: MHC-class-I-independent natural-killer-cell self-tolerance. Nat. Rev. Immunol. 5 (2005) 363-374
110. Lanier L.L. NK cell recognition. Annu. Rev. Immunol. 23 (2005) 225-274
111. Lanier L.L., Phillips J.H., Hackett Jr. J., Tutt M., and Kumar V. Natural killer cells: Definition of a cell type rather than a function. J. Immunol. 137 (1986) 2735-2739
112. Leung W., Iyengar R., Turner V., Lang P., Bader P., Conn P., Niethammer D., and Handgretinger R. Determinants of antileukemia effects of allogeneic NK cells. J. Immunol. 172 (2004) 644-650
113. Liao N.S., Bix M., Zijlstra M., Jaenisch R., and Raulet D. MHC class I deficiency: Susceptibility to natural killer (NK) cells and impaired NK activity. Science 253 (1991) 199-202
114. Ljunggren H.G., and Karre K. In search of the 'missing self': MHC molecules and NK cell recognition. Immunology Today 11 (1990) 237-244
115. Ljunggren H.G., and Malmberg K.J. Prospects for the use of NK cells in immunotherapy of human cancer. Nat. Rev. Immunol. 7 (2007) 329-339
116. Ljunggren H.G., Van Kaer L., Ploegh H.L., and Tonegawa S. Altered natural killer cell repertoire in Tap-1 mutant mice. Proc. Nat. Acad. Sci. USA 91 (1994) 6520-6524
117. Lodoen M.B., and Lanier L.L. Natural killer cells as an initial defense against pathogens. Curr. Opin. Immunol. 18 (2006) 391-398
118. Long E.O. Regulation of immune responses through inhibitory receptors. Annu. Rev. Immunol. 17 (1999) 875-904
119. Lowin-Kropf B., Kunz B., Beermann F., and Held W. Impaired natural killing of MHC class I-deficient targets by NK cells expressing a catalytically inactive form of SHP-1. J. Immunol. 165 (2000) 1314-1321
120. Lucas M., Schachterle W., Oberle K., Aichele P., and Diefenbach A. Dendritic cells prime natural killer cells by trans-presenting interleukin 15. Immunity 26 (2007) 503-517
121. Lundqvist A., McCoy J.P., Samsel L., and Childs R. Reduction of GVHD and enhanced antitumor effects after adoptive infusion of alloreactive Ly49-mismatched NK cells from MHC-matched donors. Blood 109 (2007) 3603-3606
122. Makrigiannis A.P., Pau A.T., Schwartzberg P.L., McVicar D.W., Beck T.W., and Anderson S.K. A BAC contig map of the Ly49 gene cluster in 129 mice reveals extensive differences in gene content relative to C57BL/6 mice. Genomics 79 (2002) 437-444
123. Malarkannan S., Regunathan J., Chu H., Kutlesa S., Chen Y., Zeng H., Wen R., and Wang D. Bcl10 plays a divergent role in NK cell-mediated cytotoxicity and cytokine generation. J. Immunol. 179 (2007) 3752-3762
124. Marti F., Xu C.W., Selvakumar A., Brent R., Dupont B., and King P.D. LCK-phosphorylated human killer cell-inhibitory receptors recruit and activate phosphatidylinositol 3-kinase. Proc. Nat. Acad. Sci. USA 95 (1998) 11810-11815
125. Martin M.P., Qi Y., Gao X., Yamada E., Martin J.N., Pereyra F., Colombo S., Brown E.E., Shupert W.L., Phair J., Goedert J.J., Buchbinder S., et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39 (2007) 733-740
126. Martin-Fontecha A., Thomsen L.L., Brett S., Gerard C., Lipp M., Lanzavecchia A., and Sallusto F. Induced recruitment of NK cells to lymph nodes provides IFN-gamma for T(H)1 priming. Nat. Immunol. 5 (2004) 1260-1265
127. Masuda A., Nakamura A., Maeda T., Sakamoto Y., and Takai T. Cis binding between inhibitory receptors and MHC class I can regulate mast cell activation. J. Exp. Med. 204 (2007) 907-920
128. Matsumoto N., Yokoyama W.M., Kojima S., and Yamamoto K. The NK cell MHC class I receptor Ly49A detects mutations on H-2D(d) inside and outside of the peptide binding groove. J. Immunol. 166 (2001) 4422-4428
129. McCann F.E., Eissmann P., Onfelt B., Leung R., and Davis D.M. The activating NKG2D ligand MHC class I-related chain A transfers from target cells to NK cells in a manner that allows functional consequences. J. Immunol. 178 (2007) 3418-3426
130. yMehta I.K., Smith H.R.C., Wang J., Margulies D.H., and Yokoyama W.M. A "chimeric" C57L-derived Ly49 inhibitory receptor resembling the Ly49D activation receptor. Cell Immunol. 209 (2001) 29-41
131. Mistry A.R., and O'Callaghan C.A. Regulation of ligands for the activating receptor NKG2D. Immunology 121 (2007) 439-447
132. Moffett A., and Loke C. Immunology of placentation in eutherian mammals. Nat. Rev. Immunol. 6 (2006) 584-594
133. Murphy W.J., Kumar V., and Bennett M. Rejection of bone marrow allografts by mice with severe combined immune deficiency (SCID). Evidence that natural killer cells can mediate the specificity of marrow graft rejection. J. Exp. Med. 165 (1987) 1212-1217
134. Nakamura M.C., Linnemeyer P.A., Niemi E.C., Mason L.H., Ortaldo J.R., Ryan J.C., and Seaman W.E. Mouse Ly-49D recognizes H-2Dd and activates natural killer cell cytotoxicity. J. Exp. Med. 189 (1999) 493-500
135. Nakamura M.C., Niemi E.C., Fisher M.J., Shultz L.D., Seaman W.E., and Ryan J.C. Mouse Ly-49A interrupts early signaling events in natural killer cell cytotoxicity and functionally associates with the Shp-1 tyrosine phosphatase. J. Exp. Med. 185 (1997) 673-684
136. Nasrallah J.B. Recognition and rejection of self in plant reproduction. Science 296 (2002) 305-308
137. Newman K.C., Korbel D.S., Hafalla J.C., and Riley E.M. Cross-talk with myeloid accessory cells regulates human natural killer cell interferon-gamma responses to malaria. PLoS Pathog. 2 (2006) e118
138. Newman K.C., and Riley E.M. Whatever turns you on: Accessory-cell-dependent activation of NK cells by pathogens. Nat. Rev. Immunol. 7 (2007) 279-291
139. Nicoll G., Avril T., Lock K., Furukawa K., Bovin N., and Crocker P.R. Ganglioside GD3 expression on target cells can modulate NK cell cytotoxicity via siglec-7-dependent and -independent mechanisms. Eur. J. Immunol. 33 (2003) 1642-1648
140. North J., Bakhsh I., Marden C., Pittman H., Addison E., Navarrete C., Anderson R., and Lowdell M.W. Tumor-primed human natural killer cells lyse NK-resistant tumor targets: Evidence of a two-stage process in resting NK cell activation. J. Immunol. 178 (2007) 85-94
141. Nowbakht P., Ionescu M.C., Rohner A., Kalberer C.P., Rossy E., Mori L., Cosman D., De Libero G., and Wodnar-Filipowicz A. Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias. Blood 105 (2005) 3615-3622
142. O'Keefe T.L., Williams G.T., Davies S.L., and Neuberger M.S. Hyperresponsive B cells in CD22-deficient mice. Science 274 (1996) 798-801
143. Oberg L., Johansson S., Michaelsson J., Tomasello E., Vivier E., Karre K., and Hoglund P. Loss or mismatch of MHC class I is sufficient to trigger NK cell-mediated rejection of resting lymphocytes in vivo - role of KARAP/DAP12-dependent and -independent pathways. Eur. J. Immunol. 34 (2004) 1646-1653
144. Ogasawara K., Benjamin J., Takaki R., Phillips J.H., and Lanier L.L. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat. Immunol. 6 (2005) 938-945
145. Ohlen C., Kling G., Hoglund P., Hansson M., Scangos G., Bieberich C., Jay G., and Karre K. Prevention of allogeneic bone marrow graft rejection by H-2 transgene in donor mice. Science 246 (1989) 666-668
146. Olsson M.Y., Karre K., and Sentman C.L. Altered phenotype and function of natural killer cells expressing the major histocompatibility complex receptor Ly-49 in mice transgenic for its ligand. Proc. Nat. Acad. Sci. USA 92 (1995) 1649-1653
147. Olsson-Alheim M.Y., Salcedo M., Ljunggren H.G., Karre K., and Sentman C.L. NK cell receptor calibration: Effects of MHC class I induction on killing by Ly49Ahigh and Ly49Alow NK cells. J. Immunol. 159 (1997) 3189-3194
148. Oppenheim D.E., Roberts S.J., Clarke S.L., Filler R., Lewis J.M., Tigelaar R.E., Girardi M., and Hayday A.C. Sustained localized expression of ligand for the activating NKG2D receptor impairs natural cytotoxicity in vivo and reduces tumor immunosurveillance. Nat. Immunol. 6 (2005) 928-937
149. Parham P. Taking license with natural killer cell maturation and repertoire development. Immunol. Rev. 214 (2006) 155-160
150. Pascal V., Stulberg M.J., and Anderson S.K. Regulation of class I major histocompatibility complex receptor expression in natural killer cells: One promoter is not enough. Immunol. Rev. 214 (2006) 9-21
151. Perricone R., Perricone C., De Carolis C., and Shoenfeld Y. NK cells in autoimmunity: A two-edg'd weapon of the immune system. Autoimmun. Rev. 7 (2008) 384-390
152. Plougastel B., Matsumoto K., Dubbelde C., and Yokoyama W.M. Analysis of a 1-Mb BAC contig overlapping the mouse Nkrp1 cluster of genes: Cloning of three new Nkrp1 members, Nkrp1d, Nkrp1e, and Nkrp1f. Immunogenetics 53 (2001) 592-598
153. Poggi A., Prevosto C., Massaro A.M., Negrini S., Urbani S., Pierri I., Saccardi R., Gobbi M., and Zocchi M.R. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: Role of NKp30 and NKG2D receptors. J. Immunol. 175 (2005) 6352-6360
154. Qu C.K., Nguyen S., Chen J., and Feng G.S. Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development. Blood 97 (2001) 911-914
155. Rabinovich B., Li J., Wolfson M., Lawrence W., Beers C., Chalupny J., Hurren R., Greenfield B., Miller R., and Cosman D. NKG2D splice variants: A reexamination of adaptor molecule associations. Immunogenetics 58 (2006) 81-88
156. Raulet D.H. Roles of the NKG2D immunoreceptor and its ligands. Nat. Rev. Immunol. 3 (2003) 781-790
157. Raulet D.H. Missing self recognition and self tolerance of natural killer (NK) cells. Semin. Immunol. 18 (2006) 145-150
158. Raulet D.H., and Vance R.E. Self-tolerance of natural killer cells. Nat. Rev. Immunol. 6 (2006) 520-531
159. Raulet D.H., Vance R.E., and McMahon C.W. Regulation of the natural killer cell receptor repertoire. Annu. Rev. Immunol. 19 (2001) 291-330
160. Razi N., and Varki A. Masking and unmasking of the sialic acid-binding lectin activity of CD22 (Siglec-2) on B lymphocytes. Proc. Natl. Acad. Sci. USA 95 (1998) 7469-7474
161. Riley J.K., and Yokoyama W.M. NK cell tolerance and the maternal-fetal interface. Am. J. Reprod. Immunol. 59 (2008) 371-387
162. Roda-Navarro P., Vales-Gomez M., Chisholm S.E., and Reyburn H.T. Transfer of NKG2D and MICB at the cytotoxic NK cell immune synapse correlates with a reduction in NK cell cytotoxic function. Proc. Natl. Acad. Sci. USA 103 (2006) 11258-11263
163. Roth C., Carlyle J.R., Takizawa H., and Raulet D.H. Clonal acquisition of inhibitory Ly49 receptors on developing NK cells is successively restricted and regulated by stromal class I MHC. Immunity 13 (2000) 143-153
164. Rouhi A., Gagnier L., Takei F., and Mager D.L. Evidence for epigenetic maintenance of Ly49a monoallelic gene expression. J. Immunol. 176 (2006) 2991-2999
165. Ruggeri L., Capanni M., Casucci M., Volpi I., Tosti A., Perruccio K., Urbani E., Negrin R.S., Martelli M.F., and Velardi A. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 94 (1999) 333-339
166. Ruggeri L., Capanni M., Urbani E., Perruccio K., Shlomchik W.D., Tosti A., Posati S., Rogaia D., Frassoni F., Aversa F., Martelli M.F., and Velardi A. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 295 (2002) 2097-2100
167. Salcedo M., Diehl A.D., Olsson-Alheim M.Y., Sundback J., Van Kaer L., Karre K., and Ljunggren H.G. Altered expression of Ly49 inhibitory receptors on natural killer cells from MHC class I-deficient mice. J. Immunol. 158 (1997) 3174-3180
168. Schepis D., Gunnarsson I., Eloranta M.L., Lampa J., Jacobson S.H., Karre K., and Berg L. Increased proportion of CD56(bright) natural killer cells in active and inactive systemic lupus erythematosus. Immunology (2008) Prepublished online June 18, 2008; DOI 10.1111/j.1365-2567.2008.02887.x
169. Sentman C.L., Barber M.A., Barber A., and Zhang T. NK cell receptors as tools in cancer immunotherapy. Adv. Cancer Res. 95 (2006) 249-292
170. Sentman C.L., Olsson M.Y., and Karre K. Missing self recognition by natural killer cells in MHC class I transgenic mice. A 'receptor calibration' model for how effector cells adapt to self. Seminars in Immunol. 7 (1995) 109-119
171. Sharkey A.M., Gardner L., Hiby S., Farrell L., Apps R., Masters L., Goodridge J., Lathbury L., Stewart C.A., Verma S., and Moffett A. Killer Ig-like receptor expression in uterine NK cells is biased toward recognition of HLA-C and alters with gestational age. J. Immunol. 181 (2008) 39-46
172. Sheridan C. First-in-class cancer therapeutic to stimulate natural killer cells. Nat. Biotechnol. 24 (2006) 597
173. Shultz L.D. Pleiotropic effects of deleterious alleles at the "motheaten" locus. Curr. Top Microbiol. Immunol. 137 (1988) 216-222
174. Sjostrom A., Eriksson M., Cerboni C., Johansson M.H., Sentman C.L., Karre K., and Hoglund P. Acquisition of external major histocompatibility complex class I molecules by natural killer cells expressing inhibitory ly49 receptors. J. Exp. Med. 194 (2001) 1519-1530
175. Smith H.R., Heusel J.W., Mehta I.K., Kim S., Dorner B.G., Naidenko O.V., Iizuka K., Furukawa H., Beckman D.L., Pingel J.T., Scalzo A.A., Fremont D.H., et al. Recognition of a virus-encoded ligand by a natural killer cell activation receptor. Proc. Natl. Acad. Sci. USA 99 (2002) 8826-8831
176. Spaggiari G.M., Capobianco A., Becchetti S., Mingari M.C., and Moretta L. Mesenchymal stem cell-natural killer cell interactions: Evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK-cell proliferation. Blood 107 (2006) 1484-1490
177. Sun J.C., and Lanier L.L. Tolerance of NK cells encountering their viral ligand during development. J. Exp. Med. 205 (2008) 1819-1828
178. Suzue K., Reinherz E.L., and Koyasu S. Critical role of NK but not NKT cells in acute rejection of parental bone marrow cells in F1 hybrid mice. Eur. J. Immunol. 31 (2001) 3147-3152
179. Sykes M., Harty M.W., Karlhofer F.M., Pearson D.A., Szot G., and Yokoyama W. Hematopoietic cells and radioresistant host elements influence natural killer cell differentiation. J. Exp. Med. 178 (1993) 223-229
180. Taniguchi R.T., Guzior D., and Kumar V. 2B4 inhibits NK-cell fratricide. Blood 110 (2007) 2020-2023
181. Tay C.H., Welsh R.M., and Brutkiewicz R.R. NK cell response to viral infections in beta 2-microglobulin-deficient mice. J. Immunol. 154 (1995) 780-789
182. Tormo J., Natarajan K., Margulies D.H., and Mariuzza R.A. Crystal structure of a lectin-like natural killer cell receptor bound to its MHC class I ligand. Nature 402 (1999) 623-631
183. Tripathy S.K., Keyel P.A., Yang L., Pingel J.T., Cheng T.P., Schneeberger A., and Yokoyama W.M. Continuous engagement of a self-specific activation receptor induces NK cell tolerance. J. Exp. Med. 205 (2008) 1829-1841
184. Valiante N.M., Uhrberg M., Shilling H.G., Lienertweidenbach K., Arnett K.L., Dandrea A., Phillips J.H., Lanier L.L., and Parham P. Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity 7 (1997) 739-751
185. Verheyden S., and Demanet C. NK cell receptors and their ligands in leukemia. Leukemia 22 (2008) 249-257
186. Vivier E., Nunes J.A., and Vely F. Natural killer cell signaling pathways. Science 306 (2004) 1517-1519
187. Vivier E., Tomasello E., Baratin M., Walzer T., and Ugolini S. Functions of natural killer cells. Nat. Immunol. 9 (2008) 503-510
188. Vosshenrich C.A., Garcia-Ojeda M.E., Samson-Villeger S.I., Pasqualetto V., Enault L., Richard-Le Goff O., Corcuff E., Guy-Grand D., Rocha B., Cumano A., Rogge L., Ezine S., et al. A thymic pathway of mouse natural killer cell development characterized by expression of GATA-3 and CD127. Nat. Immunol. 7 (2006) 1217-1224
189. Wagtmann N., Rajagopalan S., Winter C.C., Peruzzi M., and Long E.O. Killer cell inhibitory receptors specific for HLA-C and HLA-B identified by direct binding and by functional transfer. Immunity 3 (1995) 801-809
190. Wahle J.A., Paraiso K.H., Costello A.L., Goll E.L., Sentman C.L., and Kerr W.G. Cutting edge: Dominance by an MHC-independent inhibitory receptor compromises NK killing of complex targets. J. Immunol. 176 (2006) 7165-7169
191. Wang J., Whitman M.C., Natarajan K., Tormo J., Mariuzza R.A., and Margulies D.H. Binding of the natural killer cell inhibitory receptor Ly49A to its major histocompatibility complex class I ligand. Crucial contacts include both H-2Dd and beta 2-microglobulin. J. Biol. Chem. 277 (2002) 1433-1442
192. Wang J.W., Howson J.M., Ghansah T., Desponts C., Ninos J.M., May S.L., Nguyen K.H., Toyama-Sorimachi N., and Kerr W.G. Influence of SHIP on the NK repertoire and allogeneic bone marrow transplantation. Science 295 (2002) 2094-2097
193. Wang L.L., Chu D.T., Dokun A.O., and Yokoyama W.M. Inducible expression of the gp49B inhibitory receptor on NK cells. J. Immunol. 164 (2000) 5215-5220
194. Wiemann K., Mittrucker H.W., Feger U., Welte S.A., Yokoyama W.M., Spies T., Rammensee H.G., and Steinle A. Systemic NKG2D down-regulation impairs NK and CD8 T cell responses in vivo. J. Immunol. 175 (2005) 720-729
195. Wilhelm B.T., Gagnier L., and Mager D.L. Sequence analysis of the ly49 cluster in C57BL/6 mice: A rapidly evolving multigene family in the immune system. Genomics 80 (2002) 646-661
196. Williams N.S., Kubota A., Bennett M., Kumar V., and Takei F. Clonal analysis of NK cell development from bone marrow progenitors in vitro: Orderly acquisition of receptor gene expression. Eur. J. Immunol. 30 (2000) 2074-2082
197. Wu M.F., and Raulet D.H. Class I-deficient hemopoietic cells and nonhemopoietic cells dominantly induce unresponsiveness of natural killer cells to class I-deficient bone marrow cell grafts. J. Immunol. 158 (1997) 1628-1633
198. Yawata M., Yawata N., Draghi M., Little A.M., Partheniou F., and Parham P. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J. Exp. Med. 203 (2006) 633-645
199. Yawata M., Yawata N., Draghi M., Partheniou F., Little A.M., and Parham P. MHC class I-specific inhibitory receptors and their ligands structure diverse human NK cell repertoires towards a balance of missing-self response. Blood 112 (2008) 2369-2380
200. Yokoyama W.M. "Fundamental Immunology". In: Paul W.E. (Ed) (2008), Lippincott-Raven, New York 483-517
201. Yokoyama W.M. Mistaken notions about natural killer cells. Nat. Immunol. 9 (2008) 481-485
202. Yokoyama W.M., and Kim S. How do natural killer cells find self to achieve tolerance. Immunity 24 (2006) 249-257
203. Yokoyama W.M., and Kim S. Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol. Rev. 214 (2006) 143-154
204. Yokoyama W.M., Kim S., and French A.R. The dynamic life of natural killer cells. Annu. Rev. Immunol. 22 (2004) 405-429
205. Yokoyama W.M., and Plougastel B.F. Immune functions encoded by the natural killer gene complex. Nat. Rev. Immunol. 3 (2003) 304-316
206. Yu J., Heller G., Chewning J., Kim S., Yokoyama W.M., and Hsu K.C. Hierarchy of the human natural killer cell response is determined by class and quantity of inhibitory receptors for self-HLA-B and HLA-C ligands. J. Immunol. 179 (2007) 5977-5989
207. Yu M.C., Su L.L., Zou L., Liu Y., Wu N., Kong L., Zhuang Z.H., Sun L., Liu H.P., Hu J.H., Li D., Strominger J.L., et al. An essential function for beta-arrestin 2 in the inhibitory signaling of natural killer cells. Nat. Immunol. 9 (2008) 898-907
208. Yu Y.Y., Netuschil N., Lybarger L., Connolly J.M., and Hansen T.H. Cutting edge: Single-chain trimers of MHC class I molecules form stable structures that potently stimulate antigen-specific T cells and B cells. J. Immunol. 168 (2002) 3145-3149
209. Yusa S., and Campbell K.S. Src homology region 2-containing protein tyrosine phosphatase-2 (SHP-2) can play a direct role in the inhibitory function of killer cell Ig-like receptors in human NK cells. J. Immunol. 170 (2003) 4539-4547
210. Zhang C., Zhang J., Niu J., Zhang J., and Tian Z. Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. Cytokine 42 (2008) 128-136
211. Zhang C., Zhang J., Niu J., Zhou Z., Zhang J., and Tian Z. Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. Hum. Immunol. 69 (2008) 490-500
212. Zhang S.Q., Yang W., Kontaridis M.I., Bivona T.G., Wen G., Araki T., Luo J., Thompson J.A., Schraven B.L., Philips M.R., and Neel B.G. Shp2 regulates SRC family kinase activity and Ras/Erk activation by controlling Csk recruitment. Mol. Cell 13 (2004) 341-355
213. Zhao Y., Ohdan H., Manilay J.O., and Sykes M. NK cell tolerance in mixed allogeneic chimeras. J. Immunol. 170 (2003) 5398-5405
214. Zimmer J., Ioannidis V., and Held W. H-2D ligand expression by Ly49A+ natural killer (NK) cells precludes ligand uptake from environmental cells: Implications for NK cell function. J. Exp. Med. 194 (2001) 1531-1539